A growing number of American children are taking drugs for a wide range of chronic conditions related to childhood obesity, according to prescription data from three large organizations.
The numbers, from pharmacy plans Medco Health Solutions, Express Scripts and the marketing data collection company Verispan, indicate that hundreds of thousands of children are taking medication to treat Type 2 diabetes, high blood pressure, high cholesterol and acid reflux — all problems linked to obesity that were practically unheard-of in children two decades ago.
The data, disclosed publicly in recent mo...
read more
Weight loss treatment is always on the minds of people who are overweight or clinically obese. Some of these people employ traditional methods that help in attaining weight loss. Dieting, which is among common methods of losing weight, can have some impact on the body, but it does not help obese people to lose extra fats substantially. However, it invites trouble when the supply of nutrients to body decreases. Therefore, obese people need to take help of effective slimming pills such as Reductil that aids weight loss. These slimming pills show positive results if you complement them with healt...
read more
From a medical standpoint, Phentermine is a key player in the fight against obesity. Though proponents of a completely holistic approach to weight loss oppose the use of appetite suppressants and medications such as Phentermine, the healthcare industry in general praises the results produced by this anti-obesity medication. If used under the proper medical guidance, Phentermine will not only aid obese and overweight patients in recovering their good health but it could greatly decrease their waist lines as well. Yes, there are potential side effects related with Phentermine usage, but in patie...
read more
Sanofi-Aventis won a final green light for its weight loss pill Acomplia from Britain’s cost-effectiveness watchdog NICE on Wednesday, clearing the way for doctors to prescribe it on the state health service.
The move was expected following a positive appraisal from the National Institute for Health and Clinical Excellence (NICE) in March.
It marks a small positive for the French drugmaker’s once much-hyped medicine, which has failed to live up to early expectations.
NICE’s final guidance recommends using Acomplia, or rimonabant, as an addition to diet and exercise for obese ...
read more
